CLDI

#4986
Calidi Biotherapeutics, Inc. Common Stock
1.3 4 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.34
1.35
Intervallo Annuale
0.09
1.91
Variazione giornaliera
+2.29%
Variazione Mensile
-17.79%
Variazione di 6 mesi
+65.47%
Variazione Annuale
+77.30%
Chiusura Precedente
1.3 1
Open
1.3 5
Minimo
1.3 4
Massimo
1.3 5
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Calidi Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Calidi Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q

Calidi Biotherapeutics, Inc. current report, Q1 FY2026

Full document

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2026
Reporting Period: Fiscal year ended December 31, 2025, with operational updates for fiscal year 2026.
Context: The filing incorporates a press release (Exhibit 99.1) containing corporate updates and preliminary, unaudited financial information for the 2025 fiscal year. The company is classified as an emerging growth company.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the preliminary, unaudited financial information is based on data available as of the press release date and is subject to completion of financial closing procedures and audit adjustments. Consequently, no definitive financial metrics can be extracted from this document alone.

Material Changes

The filing does not detail specific quantitative material changes versus the prior comparable period. It notes that the preliminary financial results may differ materially from the final audited results due to ongoing closing procedures and potential adjustments.

Guidance, Outlook, and Risks

  • Operational Initiatives: The company plans to submit an Investigational New Drug (IND) application by the end of 2026.
  • Forward-Looking Statements: The report contains forward-looking statements regarding financial closing, audit finalization, and 2026 strategic priorities.
  • Risks and Contingencies: Actual results may differ materially due to:
    • Timing, cost, and results of R&D and preclinical studies.
    • Regulatory authority feedback and changes in laws.
    • Manufacturing and supply chain matters.
    • Availability of capital and resources.
    • General business, market, economic, or competitive conditions.
  • Unusual Items: The financial data presented is preliminary and unaudited, subject to final audit adjustments.

Investor Verification Checklist

  • Verify the final audited financial statements for the fiscal year ended December 31, 2025, once filed, as current figures are preliminary.
  • Monitor the status and timeline of the planned IND application submission for late 2026.
  • Review the company's most recent Form 10-K for detailed risk factors referenced in this filing.
  • Assess the company's capital availability and cash runway given the reliance on future funding for R&D initiatives.

Notizie